We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.64 | -1.40% | 45.06 | 45.20 | 44.945 | 45.12 | 868,153 | 16:31:46 |
From May 2019 to May 2024
By Dimitrios Kontos
GlaxoSmithKline PLC (GSK.LN) said Thursday that it has filed a supplemental new drug application with the U.S. Food and Drug Administration to support an expanded label for its inhaler Trelegy Ellipta.
The application is to expand the treatment's indication so that physicians can use it to treat chronic obstructive pulmonary disease patients who require triple therapy, the company said.
The pharmaceutical company submitted data from its impact study which show the efficacy and safety of the treatment in a single inhaler, it said.
The treatment was approved for use in the U.S. in September for the long-term, once-daily, treatment of chronic obstructive pulmonary disease patients and, if approved, the supplemental new drug application would broaden this indication.
Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com
(END) Dow Jones Newswires
November 23, 2017 02:48 ET (07:48 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
